Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study

J Hepatol. 2014 Jul;61(1):15-21. doi: 10.1016/j.jhep.2014.03.007. Epub 2014 Mar 17.

Abstract

Background & aims: The association between Hepatitis C virus (HCV)-infection and fracture risk is not well characterized. We compared fracture risk between HCV-seropositive (HCV-exposed) patients and the general population and between patients with cleared and chronic HCV-infection.

Methods: Outcome measures were time to first fracture at any site, time to first low-energy and first non-low-energy (other) fracture in 12,013 HCV-exposed patients from the DANVIR cohort compared with a general population control cohort (n=60,065) matched by sex and age. Within DANVIR, 4500 patients with chronic HCV-infection and 2656 patients with cleared HCV-infection were studied.

Results: Compared with population controls, HCV-exposed patients had increased overall risk of fracture [adjusted incidence rate ratio (aIRR) 2.15, 95% Confidence Interval (CI) 2.03-2.28], increased risk of low-energy fracture (aIRR 2.13, 95% CI: 1.93-2.35) and of other fracture (aIRR 2.18, 95% CI: 2.02-2.34). Compared with cleared HCV-infection, chronic HCV-infection was not associated with increased risk of fracture at any site (aIRR 1.08, 95% CI: 0.97-1.20), or other fracture (aIRR 1.04, 95% CI: 0.91-1.19). The aIRR for low-energy fracture was 1.20 (95% CI: 0.99-1.44).

Conclusions: HCV-exposed patients had increased risk of all fracture types. In contrast, overall risk of fracture did not differ between patients with chronic vs. cleared HCV-infection, although chronic HCV-infection might be associated with a small excess risk of low-energy fractures. Our study suggests that fracture risk in HCV-infected patients is multi-factorial and mainly determined by lifestyle-related factors associated with HCV-exposure.

Keywords: Chronic HCV; Cleared HCV; Comorbidity; Fracture risk.

MeSH terms

  • Adult
  • Cohort Studies
  • Denmark
  • Female
  • Fractures, Bone / etiology*
  • Hepatitis C / complications*
  • Hepatitis C / immunology
  • Hepatitis C / virology
  • Hepatitis C Antibodies / blood
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / immunology
  • Hepatitis C, Chronic / virology
  • Humans
  • Male
  • Middle Aged
  • RNA, Viral / blood
  • Risk Factors
  • Viremia / complications

Substances

  • Hepatitis C Antibodies
  • RNA, Viral